Treatment of central type lung cancer by combined cryotherapy: Experiences of 47 patients
Most patients with central type lung cancer (CTLC) are not candidates for surgery; systemic chemotherapy and external beam radiotherapy are the main treatments but have not greatly affected patient outcome. Combined percutaneous and endobronchial cryotherapy has been used successfully to treat CTLC;...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Zhikai, Zhang [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2013transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
5 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Eo-Paleoarchean detrital zircon in the Winnipeg River terrane, Western Superior Province: Provenance and implications - Strong, J.W.D. ELSEVIER, 2022, international journal of low temperature biology and medicine, Orlando, Fla |
|---|---|
| Übergeordnetes Werk: |
volume:67 ; year:2013 ; number:2 ; pages:225-229 ; extent:5 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.cryobiol.2013.07.003 |
|---|
| Katalog-ID: |
ELV033473056 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV033473056 | ||
| 003 | DE-627 | ||
| 005 | 20230625194024.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2013 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cryobiol.2013.07.003 |2 doi | |
| 028 | 5 | 2 | |a GBVA2013020000008.pica |
| 035 | |a (DE-627)ELV033473056 | ||
| 035 | |a (ELSEVIER)S0011-2240(13)00194-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 | |
| 082 | 0 | 4 | |a 570 |q DE-600 |
| 082 | 0 | 4 | |a 550 |q VZ |
| 084 | |a 38.00 |2 bkl | ||
| 100 | 1 | |a Zhikai, Zhang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Treatment of central type lung cancer by combined cryotherapy: Experiences of 47 patients |
| 264 | 1 | |c 2013transfer abstract | |
| 300 | |a 5 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Most patients with central type lung cancer (CTLC) are not candidates for surgery; systemic chemotherapy and external beam radiotherapy are the main treatments but have not greatly affected patient outcome. Combined percutaneous and endobronchial cryotherapy has been used successfully to treat CTLC; this study aimed to determine its feasibility and safety. Forty-seven patients with unresectable CTLC (22 endotracheal, 26 tracheal wall and 21 extratracheal tumors) underwent 69 sessions of combined percutaneous cryosurgery, endobronchial cryosurgery and airway stenting. The long diameter of all tumors was <5cm. Biopsy showed non-small cell lung cancer (NSCLC) in 40 patients (medium or well differentiated in 20 cases, poorly differentiated in 20) and small cell lung cancer (SCLC) in seven. Within 3days after treatment, ventilatory capacity and performance status had obviously increased and cough, signs of dyspnea, hemoptysis and atelectasis improved significantly, but symptoms of pneumothorax and pleural effusion emerged. After 2weeks, all complications had disappeared completely, as had cough. Progression-free survival (PFS) for endotracheal tumors (8±4months) was shorter than that for tracheal wall (13±6months, P <0.05) and extratracheal (14±8months, P <0.01) tumors. The PFS of NSCLC (11±5months) was significantly longer than that of SCLC (4±2months, P <0.0001). The PFS of medium or well differentiated CTLC (15±8months) was significantly longer than that of poorly differentiated CTLC (7±3months, P <0.0001). In conclusion, combined cryotherapy is a safe and effective treatment for CTLC, with PFS largely influenced by tumor location and pathologic type. | ||
| 520 | |a Most patients with central type lung cancer (CTLC) are not candidates for surgery; systemic chemotherapy and external beam radiotherapy are the main treatments but have not greatly affected patient outcome. Combined percutaneous and endobronchial cryotherapy has been used successfully to treat CTLC; this study aimed to determine its feasibility and safety. Forty-seven patients with unresectable CTLC (22 endotracheal, 26 tracheal wall and 21 extratracheal tumors) underwent 69 sessions of combined percutaneous cryosurgery, endobronchial cryosurgery and airway stenting. The long diameter of all tumors was <5cm. Biopsy showed non-small cell lung cancer (NSCLC) in 40 patients (medium or well differentiated in 20 cases, poorly differentiated in 20) and small cell lung cancer (SCLC) in seven. Within 3days after treatment, ventilatory capacity and performance status had obviously increased and cough, signs of dyspnea, hemoptysis and atelectasis improved significantly, but symptoms of pneumothorax and pleural effusion emerged. After 2weeks, all complications had disappeared completely, as had cough. Progression-free survival (PFS) for endotracheal tumors (8±4months) was shorter than that for tracheal wall (13±6months, P <0.05) and extratracheal (14±8months, P <0.01) tumors. The PFS of NSCLC (11±5months) was significantly longer than that of SCLC (4±2months, P <0.0001). The PFS of medium or well differentiated CTLC (15±8months) was significantly longer than that of poorly differentiated CTLC (7±3months, P <0.0001). In conclusion, combined cryotherapy is a safe and effective treatment for CTLC, with PFS largely influenced by tumor location and pathologic type. | ||
| 650 | 7 | |a Endobronchial cryosurgery |2 Elsevier | |
| 650 | 7 | |a Central type lung cancer |2 Elsevier | |
| 650 | 7 | |a Percutaneous cryosurgery |2 Elsevier | |
| 650 | 7 | |a Airway stenting |2 Elsevier | |
| 700 | 1 | |a Lizhi, Niu |4 oth | |
| 700 | 1 | |a Liang, Zhou |4 oth | |
| 700 | 1 | |a Jianying, Zeng |4 oth | |
| 700 | 1 | |a Fei, Yao |4 oth | |
| 700 | 1 | |a Jibing, Chen |4 oth | |
| 700 | 1 | |a Jialiang, Li |4 oth | |
| 700 | 1 | |a Kecheng, Xu |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Academic Press |a Strong, J.W.D. ELSEVIER |t Eo-Paleoarchean detrital zircon in the Winnipeg River terrane, Western Superior Province: Provenance and implications |d 2022 |d international journal of low temperature biology and medicine |g Orlando, Fla |w (DE-627)ELV008369550 |
| 773 | 1 | 8 | |g volume:67 |g year:2013 |g number:2 |g pages:225-229 |g extent:5 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.cryobiol.2013.07.003 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OPC-GGO | ||
| 936 | b | k | |a 38.00 |j Geowissenschaften: Allgemeines |q VZ |
| 951 | |a AR | ||
| 952 | |d 67 |j 2013 |e 2 |h 225-229 |g 5 | ||
| 953 | |2 045F |a 570 | ||
| author_variant |
z z zz |
|---|---|
| matchkey_str |
zhikaizhanglizhiniuliangzhoujianyingzeng:2013----:ramnocnrlyeugacryobndrohrpep |
| hierarchy_sort_str |
2013transfer abstract |
| bklnumber |
38.00 |
| publishDate |
2013 |
| allfields |
10.1016/j.cryobiol.2013.07.003 doi GBVA2013020000008.pica (DE-627)ELV033473056 (ELSEVIER)S0011-2240(13)00194-6 DE-627 ger DE-627 rakwb eng 570 570 DE-600 550 VZ 38.00 bkl Zhikai, Zhang verfasserin aut Treatment of central type lung cancer by combined cryotherapy: Experiences of 47 patients 2013transfer abstract 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Most patients with central type lung cancer (CTLC) are not candidates for surgery; systemic chemotherapy and external beam radiotherapy are the main treatments but have not greatly affected patient outcome. Combined percutaneous and endobronchial cryotherapy has been used successfully to treat CTLC; this study aimed to determine its feasibility and safety. Forty-seven patients with unresectable CTLC (22 endotracheal, 26 tracheal wall and 21 extratracheal tumors) underwent 69 sessions of combined percutaneous cryosurgery, endobronchial cryosurgery and airway stenting. The long diameter of all tumors was <5cm. Biopsy showed non-small cell lung cancer (NSCLC) in 40 patients (medium or well differentiated in 20 cases, poorly differentiated in 20) and small cell lung cancer (SCLC) in seven. Within 3days after treatment, ventilatory capacity and performance status had obviously increased and cough, signs of dyspnea, hemoptysis and atelectasis improved significantly, but symptoms of pneumothorax and pleural effusion emerged. After 2weeks, all complications had disappeared completely, as had cough. Progression-free survival (PFS) for endotracheal tumors (8±4months) was shorter than that for tracheal wall (13±6months, P <0.05) and extratracheal (14±8months, P <0.01) tumors. The PFS of NSCLC (11±5months) was significantly longer than that of SCLC (4±2months, P <0.0001). The PFS of medium or well differentiated CTLC (15±8months) was significantly longer than that of poorly differentiated CTLC (7±3months, P <0.0001). In conclusion, combined cryotherapy is a safe and effective treatment for CTLC, with PFS largely influenced by tumor location and pathologic type. Most patients with central type lung cancer (CTLC) are not candidates for surgery; systemic chemotherapy and external beam radiotherapy are the main treatments but have not greatly affected patient outcome. Combined percutaneous and endobronchial cryotherapy has been used successfully to treat CTLC; this study aimed to determine its feasibility and safety. Forty-seven patients with unresectable CTLC (22 endotracheal, 26 tracheal wall and 21 extratracheal tumors) underwent 69 sessions of combined percutaneous cryosurgery, endobronchial cryosurgery and airway stenting. The long diameter of all tumors was <5cm. Biopsy showed non-small cell lung cancer (NSCLC) in 40 patients (medium or well differentiated in 20 cases, poorly differentiated in 20) and small cell lung cancer (SCLC) in seven. Within 3days after treatment, ventilatory capacity and performance status had obviously increased and cough, signs of dyspnea, hemoptysis and atelectasis improved significantly, but symptoms of pneumothorax and pleural effusion emerged. After 2weeks, all complications had disappeared completely, as had cough. Progression-free survival (PFS) for endotracheal tumors (8±4months) was shorter than that for tracheal wall (13±6months, P <0.05) and extratracheal (14±8months, P <0.01) tumors. The PFS of NSCLC (11±5months) was significantly longer than that of SCLC (4±2months, P <0.0001). The PFS of medium or well differentiated CTLC (15±8months) was significantly longer than that of poorly differentiated CTLC (7±3months, P <0.0001). In conclusion, combined cryotherapy is a safe and effective treatment for CTLC, with PFS largely influenced by tumor location and pathologic type. Endobronchial cryosurgery Elsevier Central type lung cancer Elsevier Percutaneous cryosurgery Elsevier Airway stenting Elsevier Lizhi, Niu oth Liang, Zhou oth Jianying, Zeng oth Fei, Yao oth Jibing, Chen oth Jialiang, Li oth Kecheng, Xu oth Enthalten in Academic Press Strong, J.W.D. ELSEVIER Eo-Paleoarchean detrital zircon in the Winnipeg River terrane, Western Superior Province: Provenance and implications 2022 international journal of low temperature biology and medicine Orlando, Fla (DE-627)ELV008369550 volume:67 year:2013 number:2 pages:225-229 extent:5 https://doi.org/10.1016/j.cryobiol.2013.07.003 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-GGO 38.00 Geowissenschaften: Allgemeines VZ AR 67 2013 2 225-229 5 045F 570 |
| spelling |
10.1016/j.cryobiol.2013.07.003 doi GBVA2013020000008.pica (DE-627)ELV033473056 (ELSEVIER)S0011-2240(13)00194-6 DE-627 ger DE-627 rakwb eng 570 570 DE-600 550 VZ 38.00 bkl Zhikai, Zhang verfasserin aut Treatment of central type lung cancer by combined cryotherapy: Experiences of 47 patients 2013transfer abstract 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Most patients with central type lung cancer (CTLC) are not candidates for surgery; systemic chemotherapy and external beam radiotherapy are the main treatments but have not greatly affected patient outcome. Combined percutaneous and endobronchial cryotherapy has been used successfully to treat CTLC; this study aimed to determine its feasibility and safety. Forty-seven patients with unresectable CTLC (22 endotracheal, 26 tracheal wall and 21 extratracheal tumors) underwent 69 sessions of combined percutaneous cryosurgery, endobronchial cryosurgery and airway stenting. The long diameter of all tumors was <5cm. Biopsy showed non-small cell lung cancer (NSCLC) in 40 patients (medium or well differentiated in 20 cases, poorly differentiated in 20) and small cell lung cancer (SCLC) in seven. Within 3days after treatment, ventilatory capacity and performance status had obviously increased and cough, signs of dyspnea, hemoptysis and atelectasis improved significantly, but symptoms of pneumothorax and pleural effusion emerged. After 2weeks, all complications had disappeared completely, as had cough. Progression-free survival (PFS) for endotracheal tumors (8±4months) was shorter than that for tracheal wall (13±6months, P <0.05) and extratracheal (14±8months, P <0.01) tumors. The PFS of NSCLC (11±5months) was significantly longer than that of SCLC (4±2months, P <0.0001). The PFS of medium or well differentiated CTLC (15±8months) was significantly longer than that of poorly differentiated CTLC (7±3months, P <0.0001). In conclusion, combined cryotherapy is a safe and effective treatment for CTLC, with PFS largely influenced by tumor location and pathologic type. Most patients with central type lung cancer (CTLC) are not candidates for surgery; systemic chemotherapy and external beam radiotherapy are the main treatments but have not greatly affected patient outcome. Combined percutaneous and endobronchial cryotherapy has been used successfully to treat CTLC; this study aimed to determine its feasibility and safety. Forty-seven patients with unresectable CTLC (22 endotracheal, 26 tracheal wall and 21 extratracheal tumors) underwent 69 sessions of combined percutaneous cryosurgery, endobronchial cryosurgery and airway stenting. The long diameter of all tumors was <5cm. Biopsy showed non-small cell lung cancer (NSCLC) in 40 patients (medium or well differentiated in 20 cases, poorly differentiated in 20) and small cell lung cancer (SCLC) in seven. Within 3days after treatment, ventilatory capacity and performance status had obviously increased and cough, signs of dyspnea, hemoptysis and atelectasis improved significantly, but symptoms of pneumothorax and pleural effusion emerged. After 2weeks, all complications had disappeared completely, as had cough. Progression-free survival (PFS) for endotracheal tumors (8±4months) was shorter than that for tracheal wall (13±6months, P <0.05) and extratracheal (14±8months, P <0.01) tumors. The PFS of NSCLC (11±5months) was significantly longer than that of SCLC (4±2months, P <0.0001). The PFS of medium or well differentiated CTLC (15±8months) was significantly longer than that of poorly differentiated CTLC (7±3months, P <0.0001). In conclusion, combined cryotherapy is a safe and effective treatment for CTLC, with PFS largely influenced by tumor location and pathologic type. Endobronchial cryosurgery Elsevier Central type lung cancer Elsevier Percutaneous cryosurgery Elsevier Airway stenting Elsevier Lizhi, Niu oth Liang, Zhou oth Jianying, Zeng oth Fei, Yao oth Jibing, Chen oth Jialiang, Li oth Kecheng, Xu oth Enthalten in Academic Press Strong, J.W.D. ELSEVIER Eo-Paleoarchean detrital zircon in the Winnipeg River terrane, Western Superior Province: Provenance and implications 2022 international journal of low temperature biology and medicine Orlando, Fla (DE-627)ELV008369550 volume:67 year:2013 number:2 pages:225-229 extent:5 https://doi.org/10.1016/j.cryobiol.2013.07.003 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-GGO 38.00 Geowissenschaften: Allgemeines VZ AR 67 2013 2 225-229 5 045F 570 |
| allfields_unstemmed |
10.1016/j.cryobiol.2013.07.003 doi GBVA2013020000008.pica (DE-627)ELV033473056 (ELSEVIER)S0011-2240(13)00194-6 DE-627 ger DE-627 rakwb eng 570 570 DE-600 550 VZ 38.00 bkl Zhikai, Zhang verfasserin aut Treatment of central type lung cancer by combined cryotherapy: Experiences of 47 patients 2013transfer abstract 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Most patients with central type lung cancer (CTLC) are not candidates for surgery; systemic chemotherapy and external beam radiotherapy are the main treatments but have not greatly affected patient outcome. Combined percutaneous and endobronchial cryotherapy has been used successfully to treat CTLC; this study aimed to determine its feasibility and safety. Forty-seven patients with unresectable CTLC (22 endotracheal, 26 tracheal wall and 21 extratracheal tumors) underwent 69 sessions of combined percutaneous cryosurgery, endobronchial cryosurgery and airway stenting. The long diameter of all tumors was <5cm. Biopsy showed non-small cell lung cancer (NSCLC) in 40 patients (medium or well differentiated in 20 cases, poorly differentiated in 20) and small cell lung cancer (SCLC) in seven. Within 3days after treatment, ventilatory capacity and performance status had obviously increased and cough, signs of dyspnea, hemoptysis and atelectasis improved significantly, but symptoms of pneumothorax and pleural effusion emerged. After 2weeks, all complications had disappeared completely, as had cough. Progression-free survival (PFS) for endotracheal tumors (8±4months) was shorter than that for tracheal wall (13±6months, P <0.05) and extratracheal (14±8months, P <0.01) tumors. The PFS of NSCLC (11±5months) was significantly longer than that of SCLC (4±2months, P <0.0001). The PFS of medium or well differentiated CTLC (15±8months) was significantly longer than that of poorly differentiated CTLC (7±3months, P <0.0001). In conclusion, combined cryotherapy is a safe and effective treatment for CTLC, with PFS largely influenced by tumor location and pathologic type. Most patients with central type lung cancer (CTLC) are not candidates for surgery; systemic chemotherapy and external beam radiotherapy are the main treatments but have not greatly affected patient outcome. Combined percutaneous and endobronchial cryotherapy has been used successfully to treat CTLC; this study aimed to determine its feasibility and safety. Forty-seven patients with unresectable CTLC (22 endotracheal, 26 tracheal wall and 21 extratracheal tumors) underwent 69 sessions of combined percutaneous cryosurgery, endobronchial cryosurgery and airway stenting. The long diameter of all tumors was <5cm. Biopsy showed non-small cell lung cancer (NSCLC) in 40 patients (medium or well differentiated in 20 cases, poorly differentiated in 20) and small cell lung cancer (SCLC) in seven. Within 3days after treatment, ventilatory capacity and performance status had obviously increased and cough, signs of dyspnea, hemoptysis and atelectasis improved significantly, but symptoms of pneumothorax and pleural effusion emerged. After 2weeks, all complications had disappeared completely, as had cough. Progression-free survival (PFS) for endotracheal tumors (8±4months) was shorter than that for tracheal wall (13±6months, P <0.05) and extratracheal (14±8months, P <0.01) tumors. The PFS of NSCLC (11±5months) was significantly longer than that of SCLC (4±2months, P <0.0001). The PFS of medium or well differentiated CTLC (15±8months) was significantly longer than that of poorly differentiated CTLC (7±3months, P <0.0001). In conclusion, combined cryotherapy is a safe and effective treatment for CTLC, with PFS largely influenced by tumor location and pathologic type. Endobronchial cryosurgery Elsevier Central type lung cancer Elsevier Percutaneous cryosurgery Elsevier Airway stenting Elsevier Lizhi, Niu oth Liang, Zhou oth Jianying, Zeng oth Fei, Yao oth Jibing, Chen oth Jialiang, Li oth Kecheng, Xu oth Enthalten in Academic Press Strong, J.W.D. ELSEVIER Eo-Paleoarchean detrital zircon in the Winnipeg River terrane, Western Superior Province: Provenance and implications 2022 international journal of low temperature biology and medicine Orlando, Fla (DE-627)ELV008369550 volume:67 year:2013 number:2 pages:225-229 extent:5 https://doi.org/10.1016/j.cryobiol.2013.07.003 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-GGO 38.00 Geowissenschaften: Allgemeines VZ AR 67 2013 2 225-229 5 045F 570 |
| allfieldsGer |
10.1016/j.cryobiol.2013.07.003 doi GBVA2013020000008.pica (DE-627)ELV033473056 (ELSEVIER)S0011-2240(13)00194-6 DE-627 ger DE-627 rakwb eng 570 570 DE-600 550 VZ 38.00 bkl Zhikai, Zhang verfasserin aut Treatment of central type lung cancer by combined cryotherapy: Experiences of 47 patients 2013transfer abstract 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Most patients with central type lung cancer (CTLC) are not candidates for surgery; systemic chemotherapy and external beam radiotherapy are the main treatments but have not greatly affected patient outcome. Combined percutaneous and endobronchial cryotherapy has been used successfully to treat CTLC; this study aimed to determine its feasibility and safety. Forty-seven patients with unresectable CTLC (22 endotracheal, 26 tracheal wall and 21 extratracheal tumors) underwent 69 sessions of combined percutaneous cryosurgery, endobronchial cryosurgery and airway stenting. The long diameter of all tumors was <5cm. Biopsy showed non-small cell lung cancer (NSCLC) in 40 patients (medium or well differentiated in 20 cases, poorly differentiated in 20) and small cell lung cancer (SCLC) in seven. Within 3days after treatment, ventilatory capacity and performance status had obviously increased and cough, signs of dyspnea, hemoptysis and atelectasis improved significantly, but symptoms of pneumothorax and pleural effusion emerged. After 2weeks, all complications had disappeared completely, as had cough. Progression-free survival (PFS) for endotracheal tumors (8±4months) was shorter than that for tracheal wall (13±6months, P <0.05) and extratracheal (14±8months, P <0.01) tumors. The PFS of NSCLC (11±5months) was significantly longer than that of SCLC (4±2months, P <0.0001). The PFS of medium or well differentiated CTLC (15±8months) was significantly longer than that of poorly differentiated CTLC (7±3months, P <0.0001). In conclusion, combined cryotherapy is a safe and effective treatment for CTLC, with PFS largely influenced by tumor location and pathologic type. Most patients with central type lung cancer (CTLC) are not candidates for surgery; systemic chemotherapy and external beam radiotherapy are the main treatments but have not greatly affected patient outcome. Combined percutaneous and endobronchial cryotherapy has been used successfully to treat CTLC; this study aimed to determine its feasibility and safety. Forty-seven patients with unresectable CTLC (22 endotracheal, 26 tracheal wall and 21 extratracheal tumors) underwent 69 sessions of combined percutaneous cryosurgery, endobronchial cryosurgery and airway stenting. The long diameter of all tumors was <5cm. Biopsy showed non-small cell lung cancer (NSCLC) in 40 patients (medium or well differentiated in 20 cases, poorly differentiated in 20) and small cell lung cancer (SCLC) in seven. Within 3days after treatment, ventilatory capacity and performance status had obviously increased and cough, signs of dyspnea, hemoptysis and atelectasis improved significantly, but symptoms of pneumothorax and pleural effusion emerged. After 2weeks, all complications had disappeared completely, as had cough. Progression-free survival (PFS) for endotracheal tumors (8±4months) was shorter than that for tracheal wall (13±6months, P <0.05) and extratracheal (14±8months, P <0.01) tumors. The PFS of NSCLC (11±5months) was significantly longer than that of SCLC (4±2months, P <0.0001). The PFS of medium or well differentiated CTLC (15±8months) was significantly longer than that of poorly differentiated CTLC (7±3months, P <0.0001). In conclusion, combined cryotherapy is a safe and effective treatment for CTLC, with PFS largely influenced by tumor location and pathologic type. Endobronchial cryosurgery Elsevier Central type lung cancer Elsevier Percutaneous cryosurgery Elsevier Airway stenting Elsevier Lizhi, Niu oth Liang, Zhou oth Jianying, Zeng oth Fei, Yao oth Jibing, Chen oth Jialiang, Li oth Kecheng, Xu oth Enthalten in Academic Press Strong, J.W.D. ELSEVIER Eo-Paleoarchean detrital zircon in the Winnipeg River terrane, Western Superior Province: Provenance and implications 2022 international journal of low temperature biology and medicine Orlando, Fla (DE-627)ELV008369550 volume:67 year:2013 number:2 pages:225-229 extent:5 https://doi.org/10.1016/j.cryobiol.2013.07.003 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-GGO 38.00 Geowissenschaften: Allgemeines VZ AR 67 2013 2 225-229 5 045F 570 |
| allfieldsSound |
10.1016/j.cryobiol.2013.07.003 doi GBVA2013020000008.pica (DE-627)ELV033473056 (ELSEVIER)S0011-2240(13)00194-6 DE-627 ger DE-627 rakwb eng 570 570 DE-600 550 VZ 38.00 bkl Zhikai, Zhang verfasserin aut Treatment of central type lung cancer by combined cryotherapy: Experiences of 47 patients 2013transfer abstract 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Most patients with central type lung cancer (CTLC) are not candidates for surgery; systemic chemotherapy and external beam radiotherapy are the main treatments but have not greatly affected patient outcome. Combined percutaneous and endobronchial cryotherapy has been used successfully to treat CTLC; this study aimed to determine its feasibility and safety. Forty-seven patients with unresectable CTLC (22 endotracheal, 26 tracheal wall and 21 extratracheal tumors) underwent 69 sessions of combined percutaneous cryosurgery, endobronchial cryosurgery and airway stenting. The long diameter of all tumors was <5cm. Biopsy showed non-small cell lung cancer (NSCLC) in 40 patients (medium or well differentiated in 20 cases, poorly differentiated in 20) and small cell lung cancer (SCLC) in seven. Within 3days after treatment, ventilatory capacity and performance status had obviously increased and cough, signs of dyspnea, hemoptysis and atelectasis improved significantly, but symptoms of pneumothorax and pleural effusion emerged. After 2weeks, all complications had disappeared completely, as had cough. Progression-free survival (PFS) for endotracheal tumors (8±4months) was shorter than that for tracheal wall (13±6months, P <0.05) and extratracheal (14±8months, P <0.01) tumors. The PFS of NSCLC (11±5months) was significantly longer than that of SCLC (4±2months, P <0.0001). The PFS of medium or well differentiated CTLC (15±8months) was significantly longer than that of poorly differentiated CTLC (7±3months, P <0.0001). In conclusion, combined cryotherapy is a safe and effective treatment for CTLC, with PFS largely influenced by tumor location and pathologic type. Most patients with central type lung cancer (CTLC) are not candidates for surgery; systemic chemotherapy and external beam radiotherapy are the main treatments but have not greatly affected patient outcome. Combined percutaneous and endobronchial cryotherapy has been used successfully to treat CTLC; this study aimed to determine its feasibility and safety. Forty-seven patients with unresectable CTLC (22 endotracheal, 26 tracheal wall and 21 extratracheal tumors) underwent 69 sessions of combined percutaneous cryosurgery, endobronchial cryosurgery and airway stenting. The long diameter of all tumors was <5cm. Biopsy showed non-small cell lung cancer (NSCLC) in 40 patients (medium or well differentiated in 20 cases, poorly differentiated in 20) and small cell lung cancer (SCLC) in seven. Within 3days after treatment, ventilatory capacity and performance status had obviously increased and cough, signs of dyspnea, hemoptysis and atelectasis improved significantly, but symptoms of pneumothorax and pleural effusion emerged. After 2weeks, all complications had disappeared completely, as had cough. Progression-free survival (PFS) for endotracheal tumors (8±4months) was shorter than that for tracheal wall (13±6months, P <0.05) and extratracheal (14±8months, P <0.01) tumors. The PFS of NSCLC (11±5months) was significantly longer than that of SCLC (4±2months, P <0.0001). The PFS of medium or well differentiated CTLC (15±8months) was significantly longer than that of poorly differentiated CTLC (7±3months, P <0.0001). In conclusion, combined cryotherapy is a safe and effective treatment for CTLC, with PFS largely influenced by tumor location and pathologic type. Endobronchial cryosurgery Elsevier Central type lung cancer Elsevier Percutaneous cryosurgery Elsevier Airway stenting Elsevier Lizhi, Niu oth Liang, Zhou oth Jianying, Zeng oth Fei, Yao oth Jibing, Chen oth Jialiang, Li oth Kecheng, Xu oth Enthalten in Academic Press Strong, J.W.D. ELSEVIER Eo-Paleoarchean detrital zircon in the Winnipeg River terrane, Western Superior Province: Provenance and implications 2022 international journal of low temperature biology and medicine Orlando, Fla (DE-627)ELV008369550 volume:67 year:2013 number:2 pages:225-229 extent:5 https://doi.org/10.1016/j.cryobiol.2013.07.003 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-GGO 38.00 Geowissenschaften: Allgemeines VZ AR 67 2013 2 225-229 5 045F 570 |
| language |
English |
| source |
Enthalten in Eo-Paleoarchean detrital zircon in the Winnipeg River terrane, Western Superior Province: Provenance and implications Orlando, Fla volume:67 year:2013 number:2 pages:225-229 extent:5 |
| sourceStr |
Enthalten in Eo-Paleoarchean detrital zircon in the Winnipeg River terrane, Western Superior Province: Provenance and implications Orlando, Fla volume:67 year:2013 number:2 pages:225-229 extent:5 |
| format_phy_str_mv |
Article |
| bklname |
Geowissenschaften: Allgemeines |
| institution |
findex.gbv.de |
| topic_facet |
Endobronchial cryosurgery Central type lung cancer Percutaneous cryosurgery Airway stenting |
| dewey-raw |
570 |
| isfreeaccess_bool |
false |
| container_title |
Eo-Paleoarchean detrital zircon in the Winnipeg River terrane, Western Superior Province: Provenance and implications |
| authorswithroles_txt_mv |
Zhikai, Zhang @@aut@@ Lizhi, Niu @@oth@@ Liang, Zhou @@oth@@ Jianying, Zeng @@oth@@ Fei, Yao @@oth@@ Jibing, Chen @@oth@@ Jialiang, Li @@oth@@ Kecheng, Xu @@oth@@ |
| publishDateDaySort_date |
2013-01-01T00:00:00Z |
| hierarchy_top_id |
ELV008369550 |
| dewey-sort |
3570 |
| id |
ELV033473056 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV033473056</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625194024.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2013 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.cryobiol.2013.07.003</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2013020000008.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV033473056</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0011-2240(13)00194-6</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">570</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">550</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">38.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Zhikai, Zhang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Treatment of central type lung cancer by combined cryotherapy: Experiences of 47 patients</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2013transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">5</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Most patients with central type lung cancer (CTLC) are not candidates for surgery; systemic chemotherapy and external beam radiotherapy are the main treatments but have not greatly affected patient outcome. Combined percutaneous and endobronchial cryotherapy has been used successfully to treat CTLC; this study aimed to determine its feasibility and safety. Forty-seven patients with unresectable CTLC (22 endotracheal, 26 tracheal wall and 21 extratracheal tumors) underwent 69 sessions of combined percutaneous cryosurgery, endobronchial cryosurgery and airway stenting. The long diameter of all tumors was <5cm. Biopsy showed non-small cell lung cancer (NSCLC) in 40 patients (medium or well differentiated in 20 cases, poorly differentiated in 20) and small cell lung cancer (SCLC) in seven. Within 3days after treatment, ventilatory capacity and performance status had obviously increased and cough, signs of dyspnea, hemoptysis and atelectasis improved significantly, but symptoms of pneumothorax and pleural effusion emerged. After 2weeks, all complications had disappeared completely, as had cough. Progression-free survival (PFS) for endotracheal tumors (8±4months) was shorter than that for tracheal wall (13±6months, P <0.05) and extratracheal (14±8months, P <0.01) tumors. The PFS of NSCLC (11±5months) was significantly longer than that of SCLC (4±2months, P <0.0001). The PFS of medium or well differentiated CTLC (15±8months) was significantly longer than that of poorly differentiated CTLC (7±3months, P <0.0001). In conclusion, combined cryotherapy is a safe and effective treatment for CTLC, with PFS largely influenced by tumor location and pathologic type.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Most patients with central type lung cancer (CTLC) are not candidates for surgery; systemic chemotherapy and external beam radiotherapy are the main treatments but have not greatly affected patient outcome. Combined percutaneous and endobronchial cryotherapy has been used successfully to treat CTLC; this study aimed to determine its feasibility and safety. Forty-seven patients with unresectable CTLC (22 endotracheal, 26 tracheal wall and 21 extratracheal tumors) underwent 69 sessions of combined percutaneous cryosurgery, endobronchial cryosurgery and airway stenting. The long diameter of all tumors was <5cm. Biopsy showed non-small cell lung cancer (NSCLC) in 40 patients (medium or well differentiated in 20 cases, poorly differentiated in 20) and small cell lung cancer (SCLC) in seven. Within 3days after treatment, ventilatory capacity and performance status had obviously increased and cough, signs of dyspnea, hemoptysis and atelectasis improved significantly, but symptoms of pneumothorax and pleural effusion emerged. After 2weeks, all complications had disappeared completely, as had cough. Progression-free survival (PFS) for endotracheal tumors (8±4months) was shorter than that for tracheal wall (13±6months, P <0.05) and extratracheal (14±8months, P <0.01) tumors. The PFS of NSCLC (11±5months) was significantly longer than that of SCLC (4±2months, P <0.0001). The PFS of medium or well differentiated CTLC (15±8months) was significantly longer than that of poorly differentiated CTLC (7±3months, P <0.0001). In conclusion, combined cryotherapy is a safe and effective treatment for CTLC, with PFS largely influenced by tumor location and pathologic type.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Endobronchial cryosurgery</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Central type lung cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Percutaneous cryosurgery</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Airway stenting</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lizhi, Niu</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Liang, Zhou</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jianying, Zeng</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fei, Yao</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jibing, Chen</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jialiang, Li</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kecheng, Xu</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Academic Press</subfield><subfield code="a">Strong, J.W.D. ELSEVIER</subfield><subfield code="t">Eo-Paleoarchean detrital zircon in the Winnipeg River terrane, Western Superior Province: Provenance and implications</subfield><subfield code="d">2022</subfield><subfield code="d">international journal of low temperature biology and medicine</subfield><subfield code="g">Orlando, Fla</subfield><subfield code="w">(DE-627)ELV008369550</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:67</subfield><subfield code="g">year:2013</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:225-229</subfield><subfield code="g">extent:5</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.cryobiol.2013.07.003</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-GGO</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">38.00</subfield><subfield code="j">Geowissenschaften: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">67</subfield><subfield code="j">2013</subfield><subfield code="e">2</subfield><subfield code="h">225-229</subfield><subfield code="g">5</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">570</subfield></datafield></record></collection>
|
| author |
Zhikai, Zhang |
| spellingShingle |
Zhikai, Zhang ddc 570 ddc 550 bkl 38.00 Elsevier Endobronchial cryosurgery Elsevier Central type lung cancer Elsevier Percutaneous cryosurgery Elsevier Airway stenting Treatment of central type lung cancer by combined cryotherapy: Experiences of 47 patients |
| authorStr |
Zhikai, Zhang |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV008369550 |
| format |
electronic Article |
| dewey-ones |
570 - Life sciences; biology 550 - Earth sciences |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
570 570 DE-600 550 VZ 38.00 bkl Treatment of central type lung cancer by combined cryotherapy: Experiences of 47 patients Endobronchial cryosurgery Elsevier Central type lung cancer Elsevier Percutaneous cryosurgery Elsevier Airway stenting Elsevier |
| topic |
ddc 570 ddc 550 bkl 38.00 Elsevier Endobronchial cryosurgery Elsevier Central type lung cancer Elsevier Percutaneous cryosurgery Elsevier Airway stenting |
| topic_unstemmed |
ddc 570 ddc 550 bkl 38.00 Elsevier Endobronchial cryosurgery Elsevier Central type lung cancer Elsevier Percutaneous cryosurgery Elsevier Airway stenting |
| topic_browse |
ddc 570 ddc 550 bkl 38.00 Elsevier Endobronchial cryosurgery Elsevier Central type lung cancer Elsevier Percutaneous cryosurgery Elsevier Airway stenting |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
n l nl z l zl z j zj y f yf c j cj l j lj x k xk |
| hierarchy_parent_title |
Eo-Paleoarchean detrital zircon in the Winnipeg River terrane, Western Superior Province: Provenance and implications |
| hierarchy_parent_id |
ELV008369550 |
| dewey-tens |
570 - Life sciences; biology 550 - Earth sciences & geology |
| hierarchy_top_title |
Eo-Paleoarchean detrital zircon in the Winnipeg River terrane, Western Superior Province: Provenance and implications |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV008369550 |
| title |
Treatment of central type lung cancer by combined cryotherapy: Experiences of 47 patients |
| ctrlnum |
(DE-627)ELV033473056 (ELSEVIER)S0011-2240(13)00194-6 |
| title_full |
Treatment of central type lung cancer by combined cryotherapy: Experiences of 47 patients |
| author_sort |
Zhikai, Zhang |
| journal |
Eo-Paleoarchean detrital zircon in the Winnipeg River terrane, Western Superior Province: Provenance and implications |
| journalStr |
Eo-Paleoarchean detrital zircon in the Winnipeg River terrane, Western Superior Province: Provenance and implications |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
500 - Science |
| recordtype |
marc |
| publishDateSort |
2013 |
| contenttype_str_mv |
zzz |
| container_start_page |
225 |
| author_browse |
Zhikai, Zhang |
| container_volume |
67 |
| physical |
5 |
| class |
570 570 DE-600 550 VZ 38.00 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Zhikai, Zhang |
| doi_str_mv |
10.1016/j.cryobiol.2013.07.003 |
| dewey-full |
570 550 |
| title_sort |
treatment of central type lung cancer by combined cryotherapy: experiences of 47 patients |
| title_auth |
Treatment of central type lung cancer by combined cryotherapy: Experiences of 47 patients |
| abstract |
Most patients with central type lung cancer (CTLC) are not candidates for surgery; systemic chemotherapy and external beam radiotherapy are the main treatments but have not greatly affected patient outcome. Combined percutaneous and endobronchial cryotherapy has been used successfully to treat CTLC; this study aimed to determine its feasibility and safety. Forty-seven patients with unresectable CTLC (22 endotracheal, 26 tracheal wall and 21 extratracheal tumors) underwent 69 sessions of combined percutaneous cryosurgery, endobronchial cryosurgery and airway stenting. The long diameter of all tumors was <5cm. Biopsy showed non-small cell lung cancer (NSCLC) in 40 patients (medium or well differentiated in 20 cases, poorly differentiated in 20) and small cell lung cancer (SCLC) in seven. Within 3days after treatment, ventilatory capacity and performance status had obviously increased and cough, signs of dyspnea, hemoptysis and atelectasis improved significantly, but symptoms of pneumothorax and pleural effusion emerged. After 2weeks, all complications had disappeared completely, as had cough. Progression-free survival (PFS) for endotracheal tumors (8±4months) was shorter than that for tracheal wall (13±6months, P <0.05) and extratracheal (14±8months, P <0.01) tumors. The PFS of NSCLC (11±5months) was significantly longer than that of SCLC (4±2months, P <0.0001). The PFS of medium or well differentiated CTLC (15±8months) was significantly longer than that of poorly differentiated CTLC (7±3months, P <0.0001). In conclusion, combined cryotherapy is a safe and effective treatment for CTLC, with PFS largely influenced by tumor location and pathologic type. |
| abstractGer |
Most patients with central type lung cancer (CTLC) are not candidates for surgery; systemic chemotherapy and external beam radiotherapy are the main treatments but have not greatly affected patient outcome. Combined percutaneous and endobronchial cryotherapy has been used successfully to treat CTLC; this study aimed to determine its feasibility and safety. Forty-seven patients with unresectable CTLC (22 endotracheal, 26 tracheal wall and 21 extratracheal tumors) underwent 69 sessions of combined percutaneous cryosurgery, endobronchial cryosurgery and airway stenting. The long diameter of all tumors was <5cm. Biopsy showed non-small cell lung cancer (NSCLC) in 40 patients (medium or well differentiated in 20 cases, poorly differentiated in 20) and small cell lung cancer (SCLC) in seven. Within 3days after treatment, ventilatory capacity and performance status had obviously increased and cough, signs of dyspnea, hemoptysis and atelectasis improved significantly, but symptoms of pneumothorax and pleural effusion emerged. After 2weeks, all complications had disappeared completely, as had cough. Progression-free survival (PFS) for endotracheal tumors (8±4months) was shorter than that for tracheal wall (13±6months, P <0.05) and extratracheal (14±8months, P <0.01) tumors. The PFS of NSCLC (11±5months) was significantly longer than that of SCLC (4±2months, P <0.0001). The PFS of medium or well differentiated CTLC (15±8months) was significantly longer than that of poorly differentiated CTLC (7±3months, P <0.0001). In conclusion, combined cryotherapy is a safe and effective treatment for CTLC, with PFS largely influenced by tumor location and pathologic type. |
| abstract_unstemmed |
Most patients with central type lung cancer (CTLC) are not candidates for surgery; systemic chemotherapy and external beam radiotherapy are the main treatments but have not greatly affected patient outcome. Combined percutaneous and endobronchial cryotherapy has been used successfully to treat CTLC; this study aimed to determine its feasibility and safety. Forty-seven patients with unresectable CTLC (22 endotracheal, 26 tracheal wall and 21 extratracheal tumors) underwent 69 sessions of combined percutaneous cryosurgery, endobronchial cryosurgery and airway stenting. The long diameter of all tumors was <5cm. Biopsy showed non-small cell lung cancer (NSCLC) in 40 patients (medium or well differentiated in 20 cases, poorly differentiated in 20) and small cell lung cancer (SCLC) in seven. Within 3days after treatment, ventilatory capacity and performance status had obviously increased and cough, signs of dyspnea, hemoptysis and atelectasis improved significantly, but symptoms of pneumothorax and pleural effusion emerged. After 2weeks, all complications had disappeared completely, as had cough. Progression-free survival (PFS) for endotracheal tumors (8±4months) was shorter than that for tracheal wall (13±6months, P <0.05) and extratracheal (14±8months, P <0.01) tumors. The PFS of NSCLC (11±5months) was significantly longer than that of SCLC (4±2months, P <0.0001). The PFS of medium or well differentiated CTLC (15±8months) was significantly longer than that of poorly differentiated CTLC (7±3months, P <0.0001). In conclusion, combined cryotherapy is a safe and effective treatment for CTLC, with PFS largely influenced by tumor location and pathologic type. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-GGO |
| container_issue |
2 |
| title_short |
Treatment of central type lung cancer by combined cryotherapy: Experiences of 47 patients |
| url |
https://doi.org/10.1016/j.cryobiol.2013.07.003 |
| remote_bool |
true |
| author2 |
Lizhi, Niu Liang, Zhou Jianying, Zeng Fei, Yao Jibing, Chen Jialiang, Li Kecheng, Xu |
| author2Str |
Lizhi, Niu Liang, Zhou Jianying, Zeng Fei, Yao Jibing, Chen Jialiang, Li Kecheng, Xu |
| ppnlink |
ELV008369550 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.cryobiol.2013.07.003 |
| up_date |
2024-07-06T18:39:02.373Z |
| _version_ |
1803856004907008000 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV033473056</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625194024.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2013 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.cryobiol.2013.07.003</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2013020000008.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV033473056</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0011-2240(13)00194-6</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">570</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">550</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">38.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Zhikai, Zhang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Treatment of central type lung cancer by combined cryotherapy: Experiences of 47 patients</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2013transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">5</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Most patients with central type lung cancer (CTLC) are not candidates for surgery; systemic chemotherapy and external beam radiotherapy are the main treatments but have not greatly affected patient outcome. Combined percutaneous and endobronchial cryotherapy has been used successfully to treat CTLC; this study aimed to determine its feasibility and safety. Forty-seven patients with unresectable CTLC (22 endotracheal, 26 tracheal wall and 21 extratracheal tumors) underwent 69 sessions of combined percutaneous cryosurgery, endobronchial cryosurgery and airway stenting. The long diameter of all tumors was <5cm. Biopsy showed non-small cell lung cancer (NSCLC) in 40 patients (medium or well differentiated in 20 cases, poorly differentiated in 20) and small cell lung cancer (SCLC) in seven. Within 3days after treatment, ventilatory capacity and performance status had obviously increased and cough, signs of dyspnea, hemoptysis and atelectasis improved significantly, but symptoms of pneumothorax and pleural effusion emerged. After 2weeks, all complications had disappeared completely, as had cough. Progression-free survival (PFS) for endotracheal tumors (8±4months) was shorter than that for tracheal wall (13±6months, P <0.05) and extratracheal (14±8months, P <0.01) tumors. The PFS of NSCLC (11±5months) was significantly longer than that of SCLC (4±2months, P <0.0001). The PFS of medium or well differentiated CTLC (15±8months) was significantly longer than that of poorly differentiated CTLC (7±3months, P <0.0001). In conclusion, combined cryotherapy is a safe and effective treatment for CTLC, with PFS largely influenced by tumor location and pathologic type.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Most patients with central type lung cancer (CTLC) are not candidates for surgery; systemic chemotherapy and external beam radiotherapy are the main treatments but have not greatly affected patient outcome. Combined percutaneous and endobronchial cryotherapy has been used successfully to treat CTLC; this study aimed to determine its feasibility and safety. Forty-seven patients with unresectable CTLC (22 endotracheal, 26 tracheal wall and 21 extratracheal tumors) underwent 69 sessions of combined percutaneous cryosurgery, endobronchial cryosurgery and airway stenting. The long diameter of all tumors was <5cm. Biopsy showed non-small cell lung cancer (NSCLC) in 40 patients (medium or well differentiated in 20 cases, poorly differentiated in 20) and small cell lung cancer (SCLC) in seven. Within 3days after treatment, ventilatory capacity and performance status had obviously increased and cough, signs of dyspnea, hemoptysis and atelectasis improved significantly, but symptoms of pneumothorax and pleural effusion emerged. After 2weeks, all complications had disappeared completely, as had cough. Progression-free survival (PFS) for endotracheal tumors (8±4months) was shorter than that for tracheal wall (13±6months, P <0.05) and extratracheal (14±8months, P <0.01) tumors. The PFS of NSCLC (11±5months) was significantly longer than that of SCLC (4±2months, P <0.0001). The PFS of medium or well differentiated CTLC (15±8months) was significantly longer than that of poorly differentiated CTLC (7±3months, P <0.0001). In conclusion, combined cryotherapy is a safe and effective treatment for CTLC, with PFS largely influenced by tumor location and pathologic type.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Endobronchial cryosurgery</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Central type lung cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Percutaneous cryosurgery</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Airway stenting</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lizhi, Niu</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Liang, Zhou</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jianying, Zeng</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fei, Yao</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jibing, Chen</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jialiang, Li</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kecheng, Xu</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Academic Press</subfield><subfield code="a">Strong, J.W.D. ELSEVIER</subfield><subfield code="t">Eo-Paleoarchean detrital zircon in the Winnipeg River terrane, Western Superior Province: Provenance and implications</subfield><subfield code="d">2022</subfield><subfield code="d">international journal of low temperature biology and medicine</subfield><subfield code="g">Orlando, Fla</subfield><subfield code="w">(DE-627)ELV008369550</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:67</subfield><subfield code="g">year:2013</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:225-229</subfield><subfield code="g">extent:5</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.cryobiol.2013.07.003</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-GGO</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">38.00</subfield><subfield code="j">Geowissenschaften: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">67</subfield><subfield code="j">2013</subfield><subfield code="e">2</subfield><subfield code="h">225-229</subfield><subfield code="g">5</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">570</subfield></datafield></record></collection>
|
| score |
7.401515 |